COMPASS THERAPEUTICS, INC. Proceeds from Common Stock Issued
COMPASS THERAPEUTICS, INC. (CMPX) reported Proceeds from Common Stock Issued of $138.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-03-05
- COMPASS THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $0.00.
- COMPASS THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $138.00M.
- COMPASS THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-06-30 was $0.00.
- COMPASS THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- COMPASS THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2025 was $138.00M, a 661.88% increase from fiscal 2024.
- COMPASS THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2024 was $18.11M, a 479.43% increase from fiscal 2023.
- COMPASS THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2023 was $3.13M, a 95.90% decline from fiscal 2022.
- COMPASS THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2022 was $76.24M, a 40.56% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Common Stock 0 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 9 month as first filed | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $138.00M derived: sum of 2 quarters · filed 2026-03-05 | $138.00M derived: sum of 3 quarters · filed 2026-03-05 | $138.00M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | $138.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $138.00M derived: sum of 2 quarters · filed 2025-11-05 | $138.00M 10-Q · filed 2025-11-05 | $138.00M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $18.11M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $18.11M 10-Q · filed 2025-11-05 | $18.11M derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $18.11M 10-Q · filed 2025-08-11 | $18.11M derived: sum of 3 quarters · filed 2025-08-11 | $18.11M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $18.11M 10-Q · filed 2025-05-08 | $18.11M derived: sum of 2 quarters · filed 2025-05-08 | $18.11M derived: sum of 3 quarters · filed 2025-05-08 | $21.24M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $3.13M derived: sum of 3 quarters · filed 2025-02-27 | $3.13M 10-K · filed 2025-02-27 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.13M derived: sum of 2 quarters · filed 2024-11-12 | $3.13M 10-Q · filed 2024-11-12 | $79.36M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $3.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $3.13M 10-Q · filed 2024-08-12 | $79.36M derived: sum of 3 quarters · filed 2024-08-12 | $79.36M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | $76.24M derived: sum of 2 quarters · filed 2024-05-13 | $76.24M derived: sum of 3 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $76.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $76.24M derived: sum of 2 quarters · filed 2024-03-21 | $76.24M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $5.00K 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | |||||
| 2021-12-31 | $128.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $128.27M derived: sum of 2 quarters · filed 2023-03-15 | $128.27M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-16 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 derived: sum of 2 quarters · filed 2022-03-18 | $60.48M 10-K · filed 2022-03-18 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $60.48M 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $60.48M 10-Q · filed 2021-08-16 | |||||
| 2018-03-31 | $475.00 10-K · filed 2019-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |